gene_symbol
CD4
hgnc_id
HGNC:1678
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The DC vaccine uses HLA class II on dendritic cells to prime neoantigen-specific T cells; it does not target or kill HLA II+ DCs. Activated CD8+ T cells then kill tumor cells presenting neoantigen on HLA I via perforin/granzyme (and Fas–FasL) pathways.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
On
gated
Off
other_modifier
Coreceptor engagement stabilizing TCR–MHC II interaction on CD4+ T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06751940
disease_id_num_tar_ref
412
drug_id_num_tar_ref
1158